fashion -WSS

fashion

author：knowledge 2025-08-26 10:52:58 - browse：69852

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： White House pharmacy plagued with problems, investigation finds

WSS

Disappointing trial forces Pfizer to pivot on obesity medicine plans

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

White House pharmacy plagued with problems, investigation finds

ReNAgade cuts staff seven months after raising $300 million

Philips to halt sales of sleep apnea machines in U.S.

The Affordable Care Act has saved billions in health care costs

entertainment

fashion

knowledge

The high cost of giving birth even with insurance

Health Care Service Corp to buy Cigna Medicare Advantage plans

In Memoriam: Notable people who died in 2023

U.K. Biobank has 500,000 peoples' genome sequences available

Guidelines to prevent youth baseball injuries need more muscle

Merck CEO won’t testify in Senate, citing no expertise in drug prices

New air purifier tech could be key to improving indoor air quality

Takeda, Janssen join wearable maker to measure scratching

Tori Bowie and the unacceptable rates of Black maternal death

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

entertainment

What to do when lifesaving products contribute to climate change

Flagship Pioneering launches a new biotech in two countries

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

What to do when lifesaving products contribute to climate change

Medicare Advantage insurers face 0.2% cut to 2025 payments

Pancreatic cancer early detection could be helped by AI

knowledge

entertainment

hotspot

hotspot